PIK3CA and colorectal cancer: ETV5 may promote malignant progression of thyroid cancer through the PIK3CA signaling pathway (Meng et al., 2020), and ETV5 expression has also been associated with resistance to treatment with bevacizumab in colorectal cancer (Feng et al., 2020b).